Management of Sleep Disturbance in MDD with AUD History
Rationale for Adding Mirtazapine
- Mirtazapine is specifically recommended for patients with both depression and insomnia due to its sedative properties, which directly target the frequent awakenings this patient is experiencing 1
- The sedative effects are most beneficial when administered in the evening, allowing the medication to address nighttime sleep disturbances 1
- Limited evidence shows similar efficacy among various antidepressants for treating depression with accompanying insomnia, but mirtazapine's sedating profile makes it particularly suited for augmentation in this clinical scenario 2, 3
Practical Implementation
- Continue current Pristiq 75mg and naltrexone 50mg without modification 4
- Assess for improvement in sleep continuity within 1-2 weeks, as mirtazapine has a faster onset of action compared to other antidepressants 3
Important Caveats
- Exercise caution if the patient has obstructive sleep apnea, as mirtazapine may worsen this condition 1
- Naltrexone should be continued as it reduces relapse risk in alcohol use disorder, though it can cause hepatocellular injury and requires monitoring 4
- Avoid benzodiazepines for sleep in this patient population due to abuse potential in individuals with AUD history 5, 6
Alternative Considerations if Mirtazapine Fails
- If mirtazapine is ineffective or not tolerated, consider switching (not augmenting) to a different antidepressant rather than increasing desvenlafaxine, as the STAR*D trial showed that switching medications resulted in remission in 25% of treatment-resistant patients 3